Olmesartan Associated Enteropathy, an easily overlooked etiology of bowel disturbance: report of three cases

Olmesartan medoxomil is one of eight marketed Angiotensin II Receptor Blocker for the treatment high blood pressure. Associated Enteropathy has been described in several case reports, subsequently, United states Food and Drug Administrationincluded severe sprue-like enteropathy as an adverse effect Olmesartan. mimics celiac disease clinically pathologically. The pathologic findings are villous atrophy increased intraepithelial lymphocytes. Clinical presentation includes nausea, bloating, diarrhea weight loss. In contrast to disease, tissue transglutaminase not elevated, there no response a gluten-free diet. Several reports have effects olmesartan on gut, giving rise term Enteropathy. Clinicians should always be aware that can cause histologically similar since replacing with alternative antihypertensive drug simplify diagnostic workup provide both clinical histologic improvement. We report three cases this article. Bangladesh Crit Care J September 2022; 10(2): 154-157